Allergan plc today announced the schedule for five presentations at the American Urological Association (AUA) annual meeting.
The AUA annual meeting will be held this weekend, May 6 through 10, at the San Diego Convention Center.
Three of the poster presentations focus on overactive bladder issues. The presentation on intermittent catheterization rates after patients have been treated with OnabotulinumtoxinA is scheduled for 1 p.m. to 3 p.m. on Monday, May 9. At the same time, the results of the study on improvements in the quality of life for patients receiving long-term treatment with OnabotulinumtoxinA will be presented. The study on urinary incontinence comparing OnabotulinumtoxinA versus Solifenanin and placebo will also be presented on May 9.
The result of the double-blind study of two doses of SER120 nasal spray versus a placebo for patients with Nocturia is also on the AUA schedule. Individuals with nocturia must get up at night, often several times, to urinate.
The study on the effectiveness of LiRIS will be presented on May 9 in Room 31. The study tested the safety, tolerability and efficacy of the medication for women with ulcerative interstitial cystitis.
Alerts Sign-up